CME: Alzheimer Disease (AD) and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care
Program Description / Statement of Need:
In this online CME self-learning program:
Alzheimer Disease (AD) is a degenerative disease that most commonly affects the elderly, although it is occasionally detected as early as middle age. AD accounts for over half of all diagnosed dementia, the prevalence of which is increasing. Once there is a diagnosis of probable AD, one must determine which pharmacotherapy, if any, is most appropriate for treatment of the patient. The literature suggests that gaps in care on the part of healthcare professionals exist. While some physicians continue to use the antiquated, nonspecific term “senile dementia” as a descriptive diagnosis of AD, perhaps suggesting a lack of understanding of the gravity of the disease state or its associated pathophysiology, other report feeling uncertain at times about now to best diagnosis of the disease, particularly in its very early stages. Moreover, a number of different practice guidelines have been updated recently, and HCPs are often unable to keep up with the publishing of literature and evolution of clinical practice.
Epidemiology of and risk factors for AD
Symptomology and diagnosis of AD [Learning Objectives #1 and 2]
Treatment in patients with AD [Learning Objective #4]
Complications and barriers to optimal care in patients with AD [Learning Objective #6]
Summary, conclusions, and best practice recap
Healthcare professionals specializing in: neurology, gerontology, internal medicine, palliative care, or those who otherwise commonly care for patients with AD or who frequently encounter them or their caregivers in practice.
By the end of the session the participant will be able to:
- Describe what is presently known about the pathophysiology of AD and the challenges associated with diagnosis and treatment of AD.
- Evaluate a treatment plan for a specific patient based on degree of AD to optimize safety and efficacy, suggesting modifications for improvement.
- Identify the present treatment options currently available for management of AD* and apply them to patient cases using evidence-based medicine.
- Describe emerging drug therapies in the treatment of AD.
- Describe barriers to care and suggest therapies for treating cognitive and behavioral complications secondary to AD
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-15-020-H01-P. ACPE Accreditation effective 12/21/15, expires 12/21/17.
Release Date: December 21, 2015
Expiration Date: December 21, 2017
|Faculty:||Mario Mendez MD
Faculty Disclosure and Resolution of COI:
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Mario Mendez, MD has nothing to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.
Commercial Support Disclosure: This program is supported by an educational grant from AVANIR
Windows 2000 or above
Internet Explorer 5.5
Adobe Acrobat Reader*
Mac OS 10.2.8
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
-Read the learning objectives and faculty disclosures above
-Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
-View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
-Take the post-test
-Complete the program evaluation and CME registration. A CE certificate will be emailed to you.
Perform Pre-Test (optional)
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Complete the Symposium Evaluation and Request CE Certificate